Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. First Quarter 2026 Financial Results
INCY logo

Incyte Revenue Surges 21% to $1.27 Billion Driven by Explosive 116% Growth in Oncology Portfolio

INCY8-KFiling Date: 4/28/2026
Incyte Corporation
Description

What this story covers

Incyte Corporation reported a strong first quarter 2026 with 1 point 27 billion dollars in revenue and a 116 percent surge in its Hematology/Oncology portfolio. With 4 billion dollars in cash and 10 Phase 3 studies, the company is positioned for multiple product launches through 2027.

Story snapshot

CompanyIncyte Corporation
TickerINCY
VariantStandard detailed
Duration5:58
Filing type8-K
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000879169-26-000023
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in